{{Drugbox
| IUPAC_name = (6''Z'')-6-[butylamino-(2-chlorophenyl)methylene]-4-chloro-cyclohexa-2,4-dien-1-one
| image = Fengabine.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 80018-06-0
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 5362066
| ChemSpiderID = 4514924
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YQG0NJI5A7
| KEGG = D04149

<!--Chemical data-->
| C=17 | H=17 | Cl=2 | N=1 | O=1 
| molecular_weight = 322.23 g/mol
}}

'''Fengabine''' ('''SL-79,229''') is a [[drug]] which was investigated as an [[antidepressant]] but was never marketed.<ref name="pmid3033203">{{cite journal | vauthors = Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G | title = Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 241 | issue = 1 | pages = 245–50 |date=April 1987 | pmid = 3033203 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3033203}}</ref><ref name="pmid3033204">{{cite journal | vauthors = Scatton B, Lloyd KG, Zivkovic B | title = Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 241 | issue = 1 | pages = 251–7 |date=April 1987 | pmid = 3033204 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=3033204|display-authors=etal}}</ref> Its [[mechanism of action]] is unknown, but its antidepressant effects are reversed by [[GABAA receptor|GABA<sub>A</sub> receptor]] [[receptor antagonist|antagonist]]s like [[bicuculline]] and it has hence been labeled as [[GABAergic]]; however, it does not actually [[binding (molecular)|bind]] to [[GABA receptor]]s, nor does it inhibit [[GABA transaminase|GABA-T]].<ref name="pmid3033203"/><ref name="pmid3033204"/> In [[clinical trial]]s, fengabine's efficacy was comparable to that of the [[tricyclic antidepressant]]s, but with a more rapid [[onset of action]] and much less [[side effect]]s.<ref name="pmid2668780">{{cite journal | vauthors = Magni G, Garreau M, Orofiamma B, Palminteri R | title = Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics | journal = Neuropsychobiology | volume = 20 | issue = 3 | pages = 126–31 | year = 1989 | pmid = 2668780 | doi = 10.1159/000118485| url = }}</ref><ref name="pmid2281807">{{cite journal | vauthors = Nielsen NP, Cesana B, Zizolfi S, Ascalone V, Priore P, Morselli PL | title = Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine | journal = Acta Psychiatrica Scandinavica | volume = 82 | issue = 5 | pages = 366–71 |date=November 1990 | pmid = 2281807 | doi = 10.1111/j.1600-0447.1990.tb01402.x| url = }}</ref><ref name="pmid8471403">{{cite journal | vauthors = Fairweather DB, Kerr JS, Hilton S, Hindmarch I | title = A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers | journal = British Journal of Clinical Pharmacology | volume = 35 | issue = 3 | pages = 278–83 |date=March 1993 | pmid = 8471403 | pmc = 1381575 | doi = 10.1111/j.1365-2125.1993.tb05695.x| url = }}</ref> Notably, fengabine lacks any [[sedative]] effects.<ref name="pmid2281807"/>

== See also ==
* [[Pivagabine]]
*[[Tolgabide]] 
*[[Progabide]]

== References ==
{{Reflist}}

{{Antidepressants}}
{{Anxiolytics}}

[[Category:Chloroarenes]]
[[Category:Imines]]
[[Category:Phenols]]
[[Category:Drugs with unknown mechanisms of action]]